View ValuationThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsArix Bioscience 将来の成長Future 基準チェック /06現在、 Arix Bioscienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Capital Markets 収益成長11.1%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jan 22Arix Bioscience plc Announces Resignation of DirectorsArix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase.お知らせ • Sep 28Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023.Board Change • Sep 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Sep 15Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023New Risk • Aug 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).Board Change • Aug 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Feb 09Independent Non-Executive Chairman recently bought UK£217k worth of stockOn the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares.Board Change • Feb 08Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Jan 27Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive DirectorArix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Net income: (up UK£38.5m from 1H 2021).Board Change • Aug 11Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Chief Executive Officer Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Aug 11Arix Bioscience plc Announces Board and Committee ChangesArix Bioscience plc announced the appointments of Dr. Debra Barker, Dr. Benny Soffer, and Andrew Smith as Senior Independent Director and Non-Executive Directors respectively with immediate effect. In light of these appointments which bring the Board into compliance with the UK Corporate Governance Code, Sir Michael Bunbury is resigning from the Board with immediate effect. Debra Barker will Chair the Company’s Remuneration Committee and Andrew Smith will Chair the Company’s Audit Committee. Debra Barker is a seasoned international life sciences executive with more than 25 years’ senior and board experience from start-up biotech to big pharma companies, having held a number of senior drug development, strategic and operational roles in Novartis, Roche, SmithKline Beecham and Knoll. Debra is currently Non-Executive Director of three publicly listed biotechnology companies: Destiny Pharma plc, BergenBio in Norway and most recently, CureVac AG in Germany. Debra has a Diploma in Pharmaceutical Medicine and received a MSc in Immunology from the King's College in London and a Medical Degree from the Queens’ College, Cambridge, UK. Benny Soffer, MD is Co-Founder and Chief Investment Officer of Consonance Capital Management, a healthcare-focused public equity investment management firm. He previously completed a residency in internal medicine at Yale and served in a variety of managerial roles at Yale-New Haven Hospital. Dr. Soffer is a Clinical Assistant Professor of Medicine at Weill Cornell Medicine, receiving his MD at Emory University and his MBA at Yale University. Andrew Smith is an internationally experienced chief financial officer with strong financial and operational experience in US, Swiss and UK-based biotech and pharmaceutical companies. Andrew is currently Chief Financial Officer of Santhera Pharmaceuticals, the Swiss-based speciality pharmaceutical company, having previously held a number of senior operational and financial roles in companies including Allecra Therapeutics, Sucampo Pharmaceuticals Inc., and Retroscreen Virology (Now HVIVO Ltd). He is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.お知らせ • Aug 04Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022Arix Bioscience plc announced that they will report first half, 2022 results on Aug 10, 2022お知らせ • May 12+ 1 more updateArix Bioscience plc, Annual General Meeting, Jun 07, 2022Arix Bioscience plc, Annual General Meeting, Jun 07, 2022, at 10:00 Coordinated Universal Time. Location: offices of Brown Rudnick LLP, 8 Clifford Street, London United Kingdomお知らせ • May 04Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022Arix Bioscience plc announced that they will report fiscal year 2021 results on May 05, 2022Board Change • Apr 02Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Arix Bioscience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BATS-CHIXE:ARIXL - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20231415-2-2N/A3/31/2023-8-6-3-3N/A12/31/2022-31-28-5-5N/A9/30/2022-40-40-6-6N/A6/30/2022-50-53-8-8N/A3/31/2022-52-57-8-8N/A12/31/2021-54-61-7-7N/A9/30/20214-11-7-6N/A6/30/20216139-6-6N/A3/31/20219883-6-6N/A12/31/2020136126-7-7N/A9/30/20207872-7-7N/A6/30/20202018-8-8N/A3/31/2020-21-26-8-8N/A12/31/2019-62-70-8-8N/A9/30/2019-42-49-9-9N/A6/30/2019-22-28-9-9N/A3/31/2019155-10-10N/A12/31/20185337-11-11N/A9/30/20184731-10-10N/A6/30/20184225-9-9N/A3/31/2018259-9-9N/A12/31/20177-7-9-9N/A12/31/20161-7N/A-6N/A3/31/20160-7N/A-4N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ARIXLの予測収益成長が 貯蓄率 ( 1.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ARIXLの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ARIXLの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ARIXLの収益がUK市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ARIXLの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ARIXLの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YDiversified-financials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/12 10:21終値2023/09/14 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Arix Bioscience plc これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Maxim JacobsEdison Investment ResearchYingheng ChenHardman & Co.Dorothea HillHardman & Co.6 その他のアナリストを表示
お知らせ • Jan 22Arix Bioscience plc Announces Resignation of DirectorsArix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase.
お知らせ • Sep 28Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023.
Board Change • Sep 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 15Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023
New Risk • Aug 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
Board Change • Aug 31High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. CEO & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Feb 09Independent Non-Executive Chairman recently bought UK£217k worth of stockOn the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares.
Board Change • Feb 08Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Jan 27Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive DirectorArix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.
Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Net income: (up UK£38.5m from 1H 2021).
Board Change • Aug 11Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Chief Executive Officer Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Aug 11Arix Bioscience plc Announces Board and Committee ChangesArix Bioscience plc announced the appointments of Dr. Debra Barker, Dr. Benny Soffer, and Andrew Smith as Senior Independent Director and Non-Executive Directors respectively with immediate effect. In light of these appointments which bring the Board into compliance with the UK Corporate Governance Code, Sir Michael Bunbury is resigning from the Board with immediate effect. Debra Barker will Chair the Company’s Remuneration Committee and Andrew Smith will Chair the Company’s Audit Committee. Debra Barker is a seasoned international life sciences executive with more than 25 years’ senior and board experience from start-up biotech to big pharma companies, having held a number of senior drug development, strategic and operational roles in Novartis, Roche, SmithKline Beecham and Knoll. Debra is currently Non-Executive Director of three publicly listed biotechnology companies: Destiny Pharma plc, BergenBio in Norway and most recently, CureVac AG in Germany. Debra has a Diploma in Pharmaceutical Medicine and received a MSc in Immunology from the King's College in London and a Medical Degree from the Queens’ College, Cambridge, UK. Benny Soffer, MD is Co-Founder and Chief Investment Officer of Consonance Capital Management, a healthcare-focused public equity investment management firm. He previously completed a residency in internal medicine at Yale and served in a variety of managerial roles at Yale-New Haven Hospital. Dr. Soffer is a Clinical Assistant Professor of Medicine at Weill Cornell Medicine, receiving his MD at Emory University and his MBA at Yale University. Andrew Smith is an internationally experienced chief financial officer with strong financial and operational experience in US, Swiss and UK-based biotech and pharmaceutical companies. Andrew is currently Chief Financial Officer of Santhera Pharmaceuticals, the Swiss-based speciality pharmaceutical company, having previously held a number of senior operational and financial roles in companies including Allecra Therapeutics, Sucampo Pharmaceuticals Inc., and Retroscreen Virology (Now HVIVO Ltd). He is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant. He studied business and accounting at Liverpool John Moores University and Durham University Business School.
お知らせ • Aug 04Arix Bioscience plc to Report First Half, 2022 Results on Aug 10, 2022Arix Bioscience plc announced that they will report first half, 2022 results on Aug 10, 2022
お知らせ • May 12+ 1 more updateArix Bioscience plc, Annual General Meeting, Jun 07, 2022Arix Bioscience plc, Annual General Meeting, Jun 07, 2022, at 10:00 Coordinated Universal Time. Location: offices of Brown Rudnick LLP, 8 Clifford Street, London United Kingdom
お知らせ • May 04Arix Bioscience plc to Report Fiscal Year 2021 Results on May 05, 2022Arix Bioscience plc announced that they will report fiscal year 2021 results on May 05, 2022
Board Change • Apr 02Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.